Stryker Corporation (SYK) Stock Price & How to Invest
Last updated July 2026
Short answer
Stryker (SYK) is one of the largest pure-play medical technology companies, spanning surgical equipment, orthopaedic implants, and the Mako robotics platform, and it trades as a steady compounder that investors typically hold for durable mid-to-high-single-digit organic growth rather than deep value.
SYK stock price
As of 2026-07-23, Stryker Corporation (SYK) last closed at $318.97, down 19.6% over the past year. Over the past 52 weeks it has traded between $282.58 and $403.53.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Stryker Corporation's investor relations page. Walnut is informational, not investment advice.
What does Stryker Corporation (SYK) do?
Stryker Corporation is a global medical technology company organized into two reportable segments: MedSurg and Neurotechnology (about 62% of 2025 sales) and Orthopaedics (about 38%). Its products include surgical instruments and navigation, endoscopy and communications systems, patient handling and emergency medical equipment, minimally invasive vascular and neurovascular devices, and orthopaedic implants for hips, knees, and trauma. The company's signature differentiator is Mako robotic-arm assisted surgery, which pulls hospitals into Stryker's ecosystem of implants and enabling technology; in early 2026 Stryker recast its Orthopaedics operations into a new Ortho Tech business that pairs orthopaedic instruments with Mako and enabling technologies.
The investment picture centers on Stryker's long track record of consistent organic growth, a diversified product base that reduces reliance on any single device line, and steady acquisitions that expand its reach. In 2025 net sales reached roughly $25.1 billion, up more than 11%, and management has guided full-year 2026 organic growth of 8.0% to 9.5%. The counterweight is valuation and margin pressure: the stock carries a premium multiple, Q1 2026 was dented by a cyber incident that management expects to largely recover through the year, and adjusted margins compressed. The picture is one of a durable grower where the price already reflects a lot of the quality.
What's driving Stryker Corporation (SYK)?
1. Mako robotics and enabling technology
Mako robotic-arm assisted surgery is Stryker's core moat, driving robotic knee and hip procedures and locking hospitals into its implant and instrument ecosystem. The 2026 reorganization into an Ortho Tech business ties Mako more tightly to orthopaedic instruments. A growing installed base supports recurring implant pull-through over many years.
2. MedSurg and Neurotechnology breadth
The larger segment spans surgical equipment, patient and caregiver safety, endoscopy, medical and emergency equipment, and neurovascular devices for stroke and clot removal. It grew about 16.5% in 2025 and diversifies revenue well beyond implants. This breadth cushions cyclicality in any single product category.
3. Consistent organic growth and M&A
Stryker has a long history of mid-to-high-single-digit organic growth supplemented by frequent bolt-on acquisitions that add adjacent product lines. Management guided 2026 organic net sales growth of 8.0% to 9.5%. Procedure volume recovery and an aging population underpin steady demand for orthopaedic and surgical devices.
4. Margin expansion and cash generation
Stryker aims to expand operating margins over time through scale, manufacturing efficiency, and mix, while generating substantial free cash flow that funds a growing dividend and deals. The company raised its quarterly dividend to $0.88 per share for 2026. Recovering from the Q1 cyber disruption is a near-term margin swing factor.
What are the risks to Stryker Corporation (SYK)?
Stryker trades at a premium valuation, so any slowdown in organic growth or margin progress can pressure the multiple. Q1 2026 results were hurt by a late-quarter cyber incident that compressed adjusted margins and missed EPS estimates, and full recovery depends on catching up lost sales later in the year. The company faces strong competition in robotics and implants from Zimmer Biomet, Johnson & Johnson, Medtronic, and Smith and Nephew, plus pricing pressure from hospitals and payers. Integration risk from frequent acquisitions, currency swings, and regulatory or reimbursement changes add further uncertainty. Elective-procedure volumes can also be sensitive to macro and hospital-capacity conditions.
How is Stryker Corporation (SYK) valued? (approximate, July 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Stryker Corporation's investor relations page or your broker.
- Revenue (2025): ~$25.1B
- Q1 2026 revenue: ~$6.0B (+2.6% YoY)
- 2026 adj. EPS guidance: ~$14.90-$15.10
- Market cap: ~$127B
- Forward P/E: ~22x
- Dividend yield: ~1.0%
Stryker trades around $330 per share with a market cap near $127 billion, a premium franchise multiple that reflects its consistent growth record. Trailing P/E has run in the high-30s while the forward P/E sits closer to 22x on expected earnings growth. The Q1 2026 cyber incident dented near-term results, but management reaffirmed full-year organic growth guidance of 8.0% to 9.5%.
Who competes with Stryker Corporation (SYK)?
Orthopaedic and robotics rivals
Zimmer Biomet (ROSA robotic platform, hips and knees) and Smith and Nephew compete directly against Stryker's Mako and orthopaedic implants, while Medtronic (Mazor and Hugo) and Johnson and Johnson push into surgical robotics. These are the closest head-to-head competitors for Stryker's core growth engine.
Diversified medtech giants
Medtronic, Johnson and Johnson MedTech, Boston Scientific, and Abbott overlap across surgical, neurovascular, and MedSurg categories. They compete on scale, R&D budgets, and hospital relationships, pressuring pricing and share across Stryker's broad product portfolio.
Focused surgical and specialty players
Intuitive Surgical leads soft-tissue robotics (da Vinci) in an adjacent market, while Globus Medical, Integra LifeSciences, and Penumbra compete in spine, neuro, and vascular niches. These specialists can outpace Stryker in specific product lines even without matching its overall breadth.
How to invest in Stryker Corporation (SYK)
There are three common ways to get SYK exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so SYK sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where SYK fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Stryker Corporation (SYK)
SYK is a high-quality medtech franchise priced for consistent execution, so the debate is about paying a premium multiple for durable growth versus the near-term margin and disruption noise.
More on Stryker Corporation (SYK)
Whether SYK is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SYK a buy?, and where the stock could go from here in the SYK stock forecast.
For income investors, whether SYK pays a dividend and how the payout looks is covered in does SYK pay a dividend?
Build a basket around SYK with Walnut
Use Stryker Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Stryker do?
+
Stryker is a medical technology company that makes surgical equipment, orthopaedic implants for hips, knees, and trauma, endoscopy and neurovascular devices, and the Mako robotic surgery platform. It sells primarily to hospitals and surgeons worldwide across two segments: MedSurg and Neurotechnology, and Orthopaedics.
What are Stryker's business segments?
+
Stryker reports two segments. MedSurg and Neurotechnology was about 62% of 2025 sales and covers surgical, endoscopy, medical, and neurovascular products. Orthopaedics was about 38% and covers implants plus the Mako robotics and enabling-technology portfolio, reorganized in early 2026 into a new Ortho Tech business.
Why is Stryker's Mako robot important?
+
Mako robotic-arm assisted surgery is Stryker's key differentiator in orthopaedics. Once a hospital installs a Mako system, it tends to use Stryker implants and instruments, creating recurring pull-through revenue. A growing installed base supports Stryker's long-term orthopaedic growth.
How fast is Stryker growing?
+
Stryker grew net sales more than 11% to roughly $25.1 billion in 2025. For 2026, management guided organic net sales growth of about 8.0% to 9.5%, though Q1 2026 organic growth was slowed to around 2.4% by a cyber incident that the company expects to recover from later in the year.
Does Stryker pay a dividend?
+
Yes. Stryker pays a quarterly dividend, raised to $0.88 per share for 2026, which equates to a yield of roughly 1.0%. The company has a long history of annual dividend increases, funded by strong free cash flow, though the yield is modest given its premium valuation.
Is Stryker stock expensive?
+
Stryker trades at a premium valuation, with a trailing P/E in the high-30s and a forward P/E near 22x as of July 2026. The multiple reflects its consistent growth and quality, which means the stock can be sensitive to any slowdown in organic growth or margins.
Who are Stryker's main competitors?
+
In orthopaedics and robotics, Stryker competes with Zimmer Biomet, Smith and Nephew, Medtronic, and Johnson and Johnson. Across its broader MedSurg and neuro lines it competes with Boston Scientific, Abbott, Globus Medical, Penumbra, and others, while Intuitive Surgical leads the adjacent soft-tissue robotics market.
What are the biggest risks for Stryker?
+
Key risks include a premium valuation that leaves little room for disappointment, the near-term impact of the Q1 2026 cyber incident, intense competition in robotics and implants, hospital and payer pricing pressure, integration risk from frequent acquisitions, and sensitivity of elective-procedure volumes to macro conditions.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Stryker Corporation's investor relations page or your broker before making investment decisions.